1. Home
  2. ANL vs RGR Comparison

ANL vs RGR Comparison

Compare ANL & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$10.80

Market Cap

998.8M

Sector

N/A

ML Signal

N/A

Logo Sturm Ruger & Company Inc.

RGR

Sturm Ruger & Company Inc.

N/A

Current Price

$50.26

Market Cap

806.1M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
ANL
RGR
Founded
2004
1949
Country
Singapore
United States
Employees
N/A
1780
Industry
Ordnance And Accessories
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
998.8M
806.1M
IPO Year
2022
1994

Fundamental Metrics

Financial Performance
Metric
ANL
RGR
Price
$10.80
$50.26
Analyst Decision
Strong Buy
Buy
Analyst Count
7
2
Target Price
$29.50
★ $51.50
AVG Volume (30 Days)
268.1K
★ 533.1K
Earning Date
08-14-2026
11-04-2026
Dividend Yield
N/A
★ 0.93%
EPS Growth
N/A
N/A
EPS
N/A
★ 0.79
Revenue
N/A
★ $546,057,000.00
Revenue This Year
$243.83
$9.15
Revenue Next Year
N/A
$0.47
P/E Ratio
★ N/A
$63.11
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$28.33
52 Week High
$17.25
$54.00

Technical Indicators

Market Signals
Indicator
ANL
RGR
Relative Strength Index (RSI) 46.74 60.26
Support Level $8.95 $37.20
Resistance Level $11.90 $50.84
Average True Range (ATR) 0.99 2.20
MACD 0.25 0.21
Stochastic Oscillator 72.55 63.98

Price Performance

Historical Comparison
ANL
RGR

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About RGR Sturm Ruger & Company Inc.

Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States, and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.

Share on Social Networks: